Some of the information presented here today contains projections or other forward-looking statements regarding future events or the future financial performance of the Company.

FORWARD-LOOKING STATEMENTS AND DISCLAIMERS

These statements are based on management’s current expectations and the actual events or results may differ materially and adversely from these expectations. We refer you to the documents the Company files from time to time with the Securities and Exchange Commission, specifically, the Company’s annual report on Form 10-K, its quarterly reports on Form 10-Q, and its current reports on Form 8-K. These documents identify important risk factors that could cause the actual results to differ materially from those contained in the Company’s projections or forward-looking statements. All third-party marks—® and ™—are the property of their respective owners. Certain market and industry data has been obtained from third-party sources, which the Company believes are reliable, but the Company has not independently verified the information provided by third-party sources. Unless otherwise noted, market growth rates used in this presentation are estimates based on Company and third-party industry research.

NON-GAAP FINANCIAL MEASURES

In this presentation, the Company’s financial results and financial guidance are provided in accordance with accounting principles generally accepted in the United States (GAAP) and using certain non-GAAP financial measures. Management believes that presentation of operating results using non-GAAP financial measures provides useful supplemental information to investors and facilitates the analysis of the Company’s core operating results and comparison of operating results across reporting periods. Management also uses non-GAAP financial measures to establish budgets and to manage the Company’s business. Definitions of the non-GAAP financial measures and a reconciliation of the GAAP to non-GAAP financial results are provided in the Appendix to this presentation.

The Company does not provide forward-looking guidance on a GAAP basis for the measures on which it provides forward-looking non-GAAP guidance as the Company is unable to provide a quantitative reconciliation of forward-looking non-GAAP measures to the most directly comparable forward-looking GAAP measure, without unreasonable effort, because of the inherent difficulty in accurately forecasting the occurrence and financial impact of the various adjusting items necessary for such reconciliations that have not yet occurred, are dependent on various factors, are out of the company's control, or cannot be reasonably predicted. Such adjustments include, but are not limited to, real estate optimization and transformation initiatives, certain litigation charges and loss contingencies, costs related to acquisitions/divestitures and the related amortization, impairment and related charges, and other adjustments. For example, stock-based compensation may fluctuate based on the timing of employee stock transactions and unpredictable fluctuations in the Company's stock price. Any associated estimate of these items and its impact on GAAP performance could vary materially.
Revealing the power of genetic science – for everyone

Mission
We advance health and well-being for all, empowering every individual by revealing the answers inside each of us.

Vision
As a leader in genetic testing and precision medicine, we provide insights that help people take control of their health and enable healthcare providers to better detect, treat and prevent disease.

Moving from transformation to innovation and growth
First quarter 2024 operating and financial highlights

**Achieved Double Digit Revenue Growth; Average Selling Price (ASP) Improvements**

- **+12%** YOY revenue growth*
- **+9%** volume YOY
- **+2%** ASP YOY
- ASP improvement across majority of test portfolio

**Increasing Profitability Momentum**

- **$4 million** Adj. EBITDA significantly improved from **$(19) million** in Q1 ’23
- **$(0.01)** Adj. EPS also improved compared to **$(0.21)** in Q1 ’23

**On-Going Execution of Near-Term Strategic Priorities**

- Early wins (both Prenatal and Oncology) from competitor dislocation
- IPG assets (acq’d Q1 ’24) - integration progressing
- Reorganization of int’l ops
- Labs of the Future plan on-track
- Acceleration of investment in clinical validation studies and EMR

**Expected New Products in 2025 Support Long-Term Growth**

- Upcoming Launches
  - Foresight Universal Plus
  - FirstGene
  - Precise Liquid
  - Molecular Residual Disease (MRD)

- **Myriad-led Publications**
  - 6 manuscripts published so far in 2024
  - 5 abstracts and 3 posters to be presented at ACOG
  - 7 studies and 3 posters to be presented at ASCO

*Percentages do not sum due to rounding*
Strategic areas of focus anchored in customer requirements

Top 5 test provider requirements

Healthcare Providers (ranked by importance)

- **Utility & Validity**: Test has strongest clinical validity and utility
- **Breadth**: Lab has most comprehensive product offerings for my needs
- **Turnaround Time**: Test has fastest results/turnaround time
- **Ease of Use**: Test is easiest for me to process/lowest admin burden for my staff
- **Affordable**: Test is most affordable for my patients

4 strategic pillars
Pillars of long-term growth and profitability

Science and innovation
Top-tier science delivering products that are clinically validated and demonstrate proven utility (quality, access and cost) in real world clinical settings

Technology enabled lab operations
Automated, scalable and cost-effective laboratory operations compliant with FDA Quality Management System requirements

Elevated customer experience and commercial execution
Strong digitally enabled commercial platform

Scalable commercial, information system technology and administrative support services
Advanced regulatory, reimbursement, and revenue cycle capabilities
Positioning to lead in Oncology while streamlining operations

On-going optimization of our Oncology portfolio

**Acquisition of Intermountain Precision Genomics lab completed Feb 2024**
- Acquired Precise Tumor and Liquid assay and associated lab operations to support the launch of Precise MRD
- Expanded strategic relationship with a large, leading healthcare system

**Reorganization of European Operations and Sale of EndoPredict Business**
- Align resources to domestic opportunities while continuing to serve biopharma partners
- Continue to grow through more efficient strategic partnerships, including licensing and distribution agreements
- Entered into agreement to sell EndoPredict business and license the right to sell Prolaris in vitro diagnostic (IVD) kits outside the U.S. to Eurobio Scientific
- Myriad will continue to produce and sell EndoPredict as a LDT in the U.S.
Analytics, incentives and RCM support Q1 ‘24 revenue growth (and ASPs)

Highlights

Advanced analytics have enabled:
- Better segmentation of markets across Oncology, Women’s Health, Pharmacogenomics
- More efficiently align resources with commercial activities
- Team to provide higher value services to customers, potentially leading to higher attachment rates and improved product mix overall

Aligning commercial incentives:
- Shift to revenue-based targets (from volume)
- Incentives better aligned to achieve corporate goal of reducing no-pay rates

Revenue cycle management (RCM) initiatives

- Figures in millions
- YOY Growth +10% +2% +23% +11% +12%

Total revenue

Hereditary Cancer Revenue

Prenatal Revenue

©2024 Myriad Genetics, Inc.
Significant opportunity to accelerate MyRisk growth across Women’s Health, Imaging, Oncology and Urology

Roadmap of expected highlights

2024  MyRisk patient portal
MyRisk Medical Management Tool Enhancements
RiskScore studies
Breast Cancer Risk Assessment Program

2025  Panel Expansion | WES (whole exome sequencing)
BRAC CDx to NGS

Hereditary cancer test volume

Figures in thousands

Roadmap of expected highlights

2024  MyRisk patient portal
MyRisk Medical Management Tool Enhancements
RiskScore studies
Breast Cancer Risk Assessment Program

2025  Panel Expansion | WES (whole exome sequencing)
BRAC CDx to NGS

Hereditary cancer test volume

Figures in thousands

Q1’24 LTM Volume Growth (YOY)

Roadmap of expected highlights

2024  MyRisk patient portal
MyRisk Medical Management Tool Enhancements
RiskScore studies
Breast Cancer Risk Assessment Program

2025  Panel Expansion | WES (whole exome sequencing)
BRAC CDx to NGS

Hereditary cancer test volume

Figures in thousands

Q1’24 LTM Volume Growth (YOY)

Roadmap of expected highlights

2024  MyRisk patient portal
MyRisk Medical Management Tool Enhancements
RiskScore studies
Breast Cancer Risk Assessment Program

2025  Panel Expansion | WES (whole exome sequencing)
BRAC CDx to NGS

Hereditary cancer test volume

Figures in thousands

Q1’24 LTM Volume Growth (YOY)

Roadmap of expected highlights

2024  MyRisk patient portal
MyRisk Medical Management Tool Enhancements
RiskScore studies
Breast Cancer Risk Assessment Program

2025  Panel Expansion | WES (whole exome sequencing)
BRAC CDx to NGS

Hereditary cancer test volume

Figures in thousands

Q1’24 LTM Volume Growth (YOY)

Roadmap of expected highlights

2024  MyRisk patient portal
MyRisk Medical Management Tool Enhancements
RiskScore studies
Breast Cancer Risk Assessment Program

2025  Panel Expansion | WES (whole exome sequencing)
BRAC CDx to NGS

Hereditary cancer test volume

Figures in thousands

Q1’24 LTM Volume Growth (YOY)

Roadmap of expected highlights

2024  MyRisk patient portal
MyRisk Medical Management Tool Enhancements
RiskScore studies
Breast Cancer Risk Assessment Program

2025  Panel Expansion | WES (whole exome sequencing)
BRAC CDx to NGS

Hereditary cancer test volume

Figures in thousands

Q1’24 LTM Volume Growth (YOY)

Roadmap of expected highlights

2024  MyRisk patient portal
MyRisk Medical Management Tool Enhancements
RiskScore studies
Breast Cancer Risk Assessment Program

2025  Panel Expansion | WES (whole exome sequencing)
BRAC CDx to NGS

Hereditary cancer test volume

Figures in thousands

Q1’24 LTM Volume Growth (YOY)

Roadmap of expected highlights

2024  MyRisk patient portal
MyRisk Medical Management Tool Enhancements
RiskScore studies
Breast Cancer Risk Assessment Program

2025  Panel Expansion | WES (whole exome sequencing)
BRAC CDx to NGS

Hereditary cancer test volume

Figures in thousands

Q1’24 LTM Volume Growth (YOY)

Roadmap of expected highlights

2024  MyRisk patient portal
MyRisk Medical Management Tool Enhancements
RiskScore studies
Breast Cancer Risk Assessment Program

2025  Panel Expansion | WES (whole exome sequencing)
BRAC CDx to NGS

Hereditary cancer test volume

Figures in thousands

Q1’24 LTM Volume Growth (YOY)

Roadmap of expected highlights

2024  MyRisk patient portal
MyRisk Medical Management Tool Enhancements
RiskScore studies
Breast Cancer Risk Assessment Program

2025  Panel Expansion | WES (whole exome sequencing)
BRAC CDx to NGS

Hereditary cancer test volume

Figures in thousands

Q1’24 LTM Volume Growth (YOY)

Roadmap of expected highlights

2024  MyRisk patient portal
MyRisk Medical Management Tool Enhancements
RiskScore studies
Breast Cancer Risk Assessment Program

2025  Panel Expansion | WES (whole exome sequencing)
BRAC CDx to NGS

Hereditary cancer test volume

Figures in thousands

Q1’24 LTM Volume Growth (YOY)

Roadmap of expected highlights

2024  MyRisk patient portal
MyRisk Medical Management Tool Enhancements
RiskScore studies
Breast Cancer Risk Assessment Program

2025  Panel Expansion | WES (whole exome sequencing)
BRAC CDx to NGS

Hereditary cancer test volume

Figures in thousands

Q1’24 LTM Volume Growth (YOY)

Roadmap of expected highlights

2024  MyRisk patient portal
MyRisk Medical Management Tool Enhancements
RiskScore studies
Breast Cancer Risk Assessment Program

2025  Panel Expansion | WES (whole exome sequencing)
BRAC CDx to NGS

Hereditary cancer test volume

Figures in thousands

Q1’24 LTM Volume Growth (YOY)

Roadmap of expected highlights

2024  MyRisk patient portal
MyRisk Medical Management Tool Enhancements
RiskScore studies
Breast Cancer Risk Assessment Program

2025  Panel Expansion | WES (whole exome sequencing)
BRAC CDx to NGS

Hereditary cancer test volume

Figures in thousands

Q1’24 LTM Volume Growth (YOY)

Roadmap of expected highlights

2024  MyRisk patient portal
MyRisk Medical Management Tool Enhancements
RiskScore studies
Breast Cancer Risk Assessment Program

2025  Panel Expansion | WES (whole exome sequencing)
BRAC CDx to NGS

Hereditary cancer test volume

Figures in thousands

Q1’24 LTM Volume Growth (YOY)

Roadmap of expected highlights

2024  MyRisk patient portal
MyRisk Medical Management Tool Enhancements
RiskScore studies
Breast Cancer Risk Assessment Program

2025  Panel Expansion | WES (whole exome sequencing)
BRAC CDx to NGS

Hereditary cancer test volume

Figures in thousands

Q1’24 LTM Volume Growth (YOY)

Roadmap of expected highlights

2024  MyRisk patient portal
MyRisk Medical Management Tool Enhancements
RiskScore studies
Breast Cancer Risk Assessment Program

2025  Panel Expansion | WES (whole exome sequencing)
BRAC CDx to NGS

Hereditary cancer test volume

Figures in thousands

Q1’24 LTM Volume Growth (YOY)

Roadmap of expected highlights

2024  MyRisk patient portal
MyRisk Medical Management Tool Enhancements
RiskScore studies
Breast Cancer Risk Assessment Program

2025  Panel Expansion | WES (whole exome sequencing)
BRAC CDx to NGS

Hereditary cancer test volume

Figures in thousands

Q1’24 LTM Volume Growth (YOY)
MyRisk addresses the needs of large and growing markets

**Unaffected Market – Hereditary Screening**
- Actionable market size (US only): ~$3B
- Market penetration: 15%
- Market growth: High single digits
- MYGN market share: 30% - 35%

**Affected Market – Germline Screening**
- Actionable market size (US only): ~$1.2B
- Market penetration: 65%
- Market growth: Mid single digits
- MYGN market share: ~20%

**TOTAL U.S. POPULATION**: ~332M

**TOTAL U.S. POPULATION WHO WOULD QUALIFY FOR HCT**: ~50M*

**TOTAL NUMBER OF WOMEN WHO QUALIFY FOR HCT**: ~25M

**WOMEN WHO QUALIFY FOR HCT AND ARE ACTIVELY INVOLVED IN THEIR HEALTHCARE**: ~13M

**TOTAL NUMBER OF WOMEN WHO ARE NEWLY ELIGIBLE FOR HCT IN THE PAST YEAR**: ~800K

**TOTAL NEWLY DX PATIENTS ELIGIBLE TO RECEIVE GERMLINE SCREENING ANNUALLY**: ~860K

**PATIENTS RECEIVING GERMLINE TESTING ANNUALLY**: ~550K

Data as of 2022, source: Third party global consulting firm
*In cancers of focus
All numbers shown are 2022 estimates
Myriad’s Breast Cancer Risk Assessment Program
MyRisk with RiskScore® a clinically differentiated Hereditary Cancer Test

“All women in the U.S. should have equal access to the insights that genetic testing provides.”

Dr. Monique Gary, DO, FACS,
Breast surgeon and patient advocate at Grand View Health in Sellersville, PA

More than 50% of unaffected patients* tested with MyRisk® with RiskScore® will qualify for a change to their medical management.

*Source: Myriad internal data based on MyRisk tests reported between 9/1/2021 and 02/01/2023 ordered for unaffected patients by OBGYN & Primary Care healthcare providers.
Celebrity Cancer Diagnosis Journey Elevates the Importance of Genetic Testing Nationally

Actress Olivia Munn is sharing her recent breast cancer diagnosis journey with national audiences to elevate the importance of understanding lifetime breast cancer risk.

Through a media partnership, MyRisk® testing has been noted by Olivia Munn's provider as the genetic test she used to identify her cancer risk.

We are driving people to the MyRisk page for virtual care or to connect with us to work with their provider.

Notable #s*

2.5x web traffic WoW
3x leads generated WoW
67% traffic increase MoM

Coverage to date
KTLA-TV
People
Lipstick on the Rim podcast
SheMD podcast

What’s next?
Additional coverage expected

*Statistics are as of March 25 – April 30, 2024

What else should I know about breast cancer prevention?
If you have a family history of cancer, "it's important to talk to your doctor about genetic testing," says Aliabadi, whose office recommends patients starting at age 25 take the MyRisk Hereditary Cancer Test, which includes free genetic counseling and evaluates 48 genes associated with hereditary cancer risk. The test, which is in-network with most commercial insurance plans according to its site, also calculates your lifetime risk breast cancer score.

"...and with Olivia, I used a test from Myriad called MyRisk."
– Dr. Thaïs Aliabadi, KTLA Los Angeles

"RiskScore is Tyer-Cuzick plus little genetic markers in your DNA that individually cannot hurt you, but if you have a lot of those markers, it can push your lifetime risk up."
– Dr. Thaïs Aliabadi, Lipstick on the Rim podcast
A market that continues to grow with potential tailwinds from guideline expansion

<table>
<thead>
<tr>
<th>Actionable market size (US only)*</th>
<th>Market penetration*</th>
<th>Market growth**</th>
<th>MYGN market share*</th>
</tr>
</thead>
<tbody>
<tr>
<td>~$1.3B</td>
<td>45-55%</td>
<td>Low single digits</td>
<td>~40-50%</td>
</tr>
<tr>
<td>~$950M</td>
<td>40-50%</td>
<td>Low single digits</td>
<td>Mid teens</td>
</tr>
</tbody>
</table>

*Data as of 2022 from third-party global consulting firm and internal Company estimates
**Expected

Roadmap of expected highlights

2024 Foresight on NovaSeq
Various Prequel studies
Foresight Universal Plus

2025 FirstGene Launch

Prenatal test volume excl. SneakPeek
Figures in thousands

Q1’24 LTM Volume Growth (YOY)

+15%

+12%
+12%

+20%
+17%

+11%

Q1 ‘22 Q4 ’22 Q1 ’23 Q2 ’23 Q3 ’23 Q4 ’23 Q1 ’24

YOY Growth

0% (1%) +12% +12% +20% +17% +11%
Strong commercial execution driving significant volume growth in the last twelve months

**Roadmap of expected highlights**

- **2024**
  - Health Economic Outcome Research (HEOR) study***
  - Significant opportunity to improve payor coverage and ASP

- **2025**
  - Postpartum Clin Dev Protocol & Study

---

<table>
<thead>
<tr>
<th>Actionable market size (US only)*</th>
<th>Market penetration*</th>
<th>Market growth**</th>
<th>MYGN market share*</th>
</tr>
</thead>
<tbody>
<tr>
<td>~$5B</td>
<td>15%</td>
<td>Mid teens</td>
<td>55-60%</td>
</tr>
</tbody>
</table>

---

**GeneSight test volume**

Figures in thousands

- Q1’24 LTM Volume Growth (YOY) +19%

---

**Table**

<table>
<thead>
<tr>
<th>Q3 ‘22</th>
<th>Q4 ‘22</th>
<th>Q1 ‘23</th>
<th>Q2 ‘23</th>
<th>Q3 ‘23</th>
<th>Q4 ‘23</th>
<th>Q1 ‘24</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>125</td>
</tr>
</tbody>
</table>

**YOY Growth**

- Q3 ’22: +34%
- Q4 ’22: +22%
- Q1 ‘23: +31%
- Q2 ‘23: +23%
- Q3 ‘23: +19%
- Q4 ‘23: +21%
- Q1 ‘24: +13%

---

*Data as of 2022 from third-party global consulting firm and internal Company estimates

**Expected

***This study used data from the Optum Labs Data Warehouse, composed of de-identified administrative claims data for both commercially insured and Medicare Advantage enrollees. The claims data were linked on a de-identified basis with PGx test results.
Active expansion of high-quality testing pipeline, addressing real-world community needs

### Women's Health

**FirstGene™**
Multiple prenatal screening

- Integrated assay for NIPS + carrier screen + fetal recessive status + feto-maternal blood compatibility on a single blood draw on one person

- Faster turnaround time
- Estimated 3x lower cost of goods
- Established reimbursement

### Oncology

**Foresight™**
Expanded carrier screen

- Pioneering expanded carrier screen that uses NGS to find pathogenic variants underlying recessive disease

- Merged couple reporting
- Fully automated lab workflow drives low COGS

**Precise™ Tumor**
Robust tumor profiling & therapy selection

- Pan-cancer comprehensive genomic profiling test using Illumina TruSight Oncology 500; may serve as first-line offering

- Panel size ~2x size (500 genes) of lead competitor; uses both DNA/RNA; ease of use as part of Precise Oncology Solutions
- Established reimbursement path

**Precise™ Liquid**
Robust tumor profiling & therapy selection

- Comprehensive genomic profiling test; may serve as first-line offering or as reflex if solid tumor is insufficient

- Panel size ~2x size (500 genes) of lead competitor; uses DNA; ease of use as part of Precise Oncology Solutions
- Established reimbursement path

**Precise™ MRD**
Molecular residual disease monitoring

- Monitoring test based on whole genome sequencing to deeply interrogate tumor, detect recurrence earlier and help guide treatment decisions

- Targets 10x variants
- Known path to reimbursement
Sam Raha
Chief Operating Officer
Advancing the Labs of the Future program

Objective
To drive innovation and operational excellence at scale to deliver high quality results with shortened turnaround times and lower COGs

Q1 ‘24 Highlights
On-track, executing against our strategy
- Passed NY State Clinical Laboratory Inspection (SLC)
- Completed phase 1 of MRD move (SLC)
- Completed CA and CLIA inspections (SSF)
- Completed Prequel validation (SSF)
Intermountain Precision Genomics
On track with integration

Q1
Deal announced
January 18th
Deal closed
February 1st
Myriad acquires:
• Select assets of Intermountain Precision Genomics
• Precise Tumor and Liquid Assays

Q2
• Employee retention
• Testing continuity and improvement
• Lab move planning and initiation

Q3
• Continue lab move
• Systems integration and validation
• Start processing samples

Q4
• Complete lab move
• Monitor & improve sample processing and reporting
• Pre-launch preparation for Precise Liquid
Positioned to Succeed in an Increasingly Regulated Environment

Myriad Genetics Initial Perspective on FDA Ruling on LDT Oversight

Well-positioned to meet FDA requirements

- Portfolio of molecular diagnostics tests meets CAP, CLIA and NY State requirements
- Strong Quality Assurance and Regulatory Affairs Organization

Deep experience with the FDA, including:

- Collaborating with FDA on regulatory submissions and achieving product approvals
- Building and maintaining a robust, FDA-compliant Quality Management System (QMS)

Plan to proactively engage with the FDA

- Facilitate timely regulatory feedback across product portfolio

At Myriad Genetics, we view patient safety and increasing patient access to diagnostic tests as essential to our mission of advancing health and well-being for all.
First Quarter 2024 Operational highlights fueling our growth

<table>
<thead>
<tr>
<th>Team Engagement</th>
<th>Market Perception and Customer Service Levels</th>
<th>Efficiency &amp; Productivity</th>
<th>Revenue Cycle</th>
</tr>
</thead>
<tbody>
<tr>
<td>86%</td>
<td>74&lt;br&gt;<strong>Net Promoter Score</strong> among current Myriad providers ordering across our testing portfolio (Feb ‘24)<strong>&lt;br&gt;86% of our team rate Myriad as a “Great Place To Work” (2023)</strong>&lt;br&gt;Employee turnover, approximately half of what it was in 2021**</td>
<td>&lt; 6.0 days&lt;br&gt;Rapid turn-around times critical for patients making time-sensitive care decisions**&lt;br&gt;47% of genetic counselors surveyed in 2023 had a more positive impression of Myriad because of our contributions to ClinVar**&lt;br&gt;+11.5% YOY Commercial productivity increase with improved sales planning, automation and process optimization**</td>
<td><strong>ASP +2%</strong>&lt;br&gt;YOY increase (Q1 ’24 vs. Q1 ‘23)&lt;br&gt;ASP increase driven by expanding payer coverage and RCM progress**&lt;br&gt;Industry leading Days Sales Outstanding (DSO) improved 1 day from Q4 ‘23**</td>
</tr>
</tbody>
</table>

*All data as of first quarter, 2024, except as otherwise noted*

*Brand Equity Research 2023. How does knowing that Myriad Genetics has begun sharing variant data classifications to public database ClinVar affect how you feel about Myriad compared to their competitors?*
Hereditary cancer test, Prenatal and GeneSight revenue drive performance in Q1 ‘24

Select test revenue and growth rates
All figures in millions, except growth rates

Hereditary Cancer

<table>
<thead>
<tr>
<th>Q1 ’23</th>
<th>Q1 ’24</th>
</tr>
</thead>
<tbody>
<tr>
<td>$70</td>
<td>$88</td>
</tr>
</tbody>
</table>

16% 

Prenatal

<table>
<thead>
<tr>
<th>Q1 ’23</th>
<th>Q1 ’24</th>
</tr>
</thead>
<tbody>
<tr>
<td>$50</td>
<td>$60</td>
</tr>
</tbody>
</table>

22% 

Pharmacogenomics

<table>
<thead>
<tr>
<th>Q1 ’23</th>
<th>Q1 ’24</th>
</tr>
</thead>
<tbody>
<tr>
<td>$50</td>
<td>$60</td>
</tr>
</tbody>
</table>

21%

Hereditary cancer testing highlights:

Seventh consecutive quarter of YOY growth in test volumes

7% YOY growth in Q1 ‘24 HCT volumes in Women’s Health

10% YOY growth in Q1 ‘24 HCT volumes in Oncology
Focused efforts designed to drive near-term improvement in no-pay rate

Focus on the ground game
Payor compliance to current guidelines

01 State biomarker laws leading to new coverage opportunities

02 Bolster “go-to-market” messaging and targeting for GeneSight

Process improvements
Revenue cycle operations

01 Accelerate large-scale EMR integrations to mitigate issues with missing data

02 Deploy Unified Order Management to reduce friction for Billing

03 AI-enhanced insights to rapidly surface and resolve emerging payment hot spots

04 Optimize customer journey for Direct Pay for those who don’t meet guidelines or don’t have coverage

Augment the pre-auth team
Hire and add robotic processing (RPA)

01 Invest in added team members to keep up with double-digit growth and associated increased authorizations

02 Add RPA to off-load repetitive tasks

Q1 ASP +2% improvement YOY reflecting expanded payer coverage and momentum of RCM initiatives
2023 and Q1 ‘24 financial progression by quarter

All figures in millions, except per share amounts and percentages

<table>
<thead>
<tr>
<th>Total revenue</th>
<th>Adjusted Gross Margin*</th>
<th>Adjusted Operating Expense*</th>
<th>Adjusted EPS*</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>$195</td>
<td>$155</td>
<td>$0.00</td>
<td>(0.01)</td>
</tr>
<tr>
<td>Q4 '22</td>
<td>Q1 '23</td>
<td>Q2 '23</td>
<td>Q3 '23</td>
</tr>
<tr>
<td>177.8</td>
<td>181.2</td>
<td>183.5</td>
<td>192.2</td>
</tr>
<tr>
<td>Q1 '24</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>$155</td>
<td>$115</td>
<td>($0.24)</td>
<td>(0.21)</td>
</tr>
<tr>
<td>Q4 '22</td>
<td>Q1 '23</td>
<td>Q2 '23</td>
<td>Q3 '23</td>
</tr>
<tr>
<td>138.6</td>
<td>134.5</td>
<td>137.3</td>
<td>139.1</td>
</tr>
<tr>
<td>Q4 '23</td>
<td>Q1 '24</td>
<td></td>
<td></td>
</tr>
<tr>
<td>202.2</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

YOY First Quarter 2024

12% 72% 4%

All figures in millions, except per share amounts and percentages

*GAAP to non-GAAP reconciliations can be found in the appendix.
Positive adjusted EBITDA in Q1 ’24 and solid financial flexibility

$ in millions

<table>
<thead>
<tr>
<th>Description</th>
<th>1Q ’23</th>
<th>1Q ’24</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total cash, cash equivalents and marketable investment securities at end of first quarter of 2024</td>
<td>$104.3</td>
<td>$145.6</td>
</tr>
<tr>
<td>Amount available to draw under the asset-based credit facility*</td>
<td>41.3</td>
<td></td>
</tr>
<tr>
<td>Estimated total available cash and cash equivalents and availability under credit facility at end of first quarter of 2024</td>
<td></td>
<td>$145.6</td>
</tr>
</tbody>
</table>

Adjusted EBITDA

$ in millions

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Adjusted EBITDA</th>
</tr>
</thead>
<tbody>
<tr>
<td>1Q ’23</td>
<td>-$18.8</td>
</tr>
<tr>
<td>1Q ’24</td>
<td>$4.0</td>
</tr>
</tbody>
</table>

Q1 ’24 adjusted EBITDA of $4.0 million versus $(18.8) million in Q1 ’23

Expected 2024 cash burn concentrated in seasonally-high Q1; Q1 ’24 Adj. operating cash flow of $(9.3) million vs. $(25.1) million in Q1 ’23

Operating cash flow expected to be positive for remainder of 2024

The availability under the ABL facility as of March 31, 2024 was $41.3 million, subject to minimum availability requirements of $25 million.
## Reiterate 2024 financial guidance

*All figures in millions, except per share amounts and percentages*

<table>
<thead>
<tr>
<th></th>
<th>2024 FINANCIAL GUIDANCE</th>
<th>EXPECTED YEAR-OVER-YEAR CHANGE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total revenue</td>
<td>$820 - $840</td>
<td>9% - 11%</td>
</tr>
<tr>
<td>Gross margin %</td>
<td>69.5% - 70.5%</td>
<td>50 – 150 bps</td>
</tr>
<tr>
<td>Adjusted operating expenses*</td>
<td>$572 - $582</td>
<td>5% - 7%</td>
</tr>
<tr>
<td>Adjusted EBITDA*</td>
<td>$20 - $30</td>
<td>$31 - $41</td>
</tr>
<tr>
<td>Adjusted EPS*</td>
<td>$0.00 - $0.05</td>
<td>+$0.27 - $0.32</td>
</tr>
</tbody>
</table>

*The company does not forecast GAAP operating expenses, earnings before interest, tax, depreciation, or amortization (EBITDA), and earnings per share because it cannot predict certain elements that are included in reported GAAP results. See the statement on Non-GAAP Financial Measures at the beginning of this presentation and the Appendix to this presentation for more information about the use of non-GAAP financial measures.

Assumes currency rates as of May 7, 2024
Well positioned to take advantage of future market opportunities

- **Annual revenue growth expected to accelerate to 10%+ in ‘24–‘26**
  - Reiterate 2024 full-year revenue guidance of $820 - $840 million reflecting expected annual growth of 9-11% over 2023

- **Right to win with core products driving market share gains**
  - Enhanced commercial execution generating volume growth as adoption rates and competitive position improves

- **Pipeline addresses large growth markets**
  - Robust and differentiated product pipeline expected to open access to incremental multi-billion-dollar markets

- **Operating leverage, profitability, and positive cash flow**
  - Strength of business model, technology platform and enhanced laboratory capabilities expected to drive operating leverage, adjusted profitability and positive adjusted cash flow in 2024–2026

- **Ongoing Portfolio Repositioning and Capital deployment**
  - Disciplined capital deployment; continue to invest in high ROI opportunities within core channels
Q&A
Reconciliation of GAAP to Non-GAAP Financial Measures for the Three Months ended March 31, 2024 and 2023

(unaudited data in millions, except percentages)

<table>
<thead>
<tr>
<th></th>
<th>Three months ended March 31,</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>2024</td>
</tr>
<tr>
<td><strong>Adjusted Gross Margin</strong></td>
<td></td>
</tr>
<tr>
<td>GAAP Gross Profit (1)</td>
<td>$137.6</td>
</tr>
<tr>
<td>Acquisition - amortization of intangible assets</td>
<td>0.3</td>
</tr>
<tr>
<td>Equity compensation</td>
<td>0.3</td>
</tr>
<tr>
<td>Other adjustments</td>
<td>0.3</td>
</tr>
<tr>
<td>Adjusted Gross Profit</td>
<td>$138.5</td>
</tr>
<tr>
<td>Adjusted Gross Margin</td>
<td>68.5%</td>
</tr>
</tbody>
</table>

(1) Consists of total revenues less cost of testing revenue from the Condensed Consolidated Statements of Operations.

<table>
<thead>
<tr>
<th></th>
<th>Three months ended March 31,</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>2024</td>
</tr>
<tr>
<td><strong>Adjusted Operating Expenses</strong></td>
<td></td>
</tr>
<tr>
<td>GAAP Operating Expenses (1)</td>
<td>$165.5</td>
</tr>
<tr>
<td>Acquisition - amortization of intangible assets</td>
<td>(10.4)</td>
</tr>
<tr>
<td>Equity compensation</td>
<td>(11.6)</td>
</tr>
<tr>
<td>Real estate optimization</td>
<td>(1.2)</td>
</tr>
<tr>
<td>Transformation initiatives</td>
<td>1.9</td>
</tr>
<tr>
<td>Legal charges, net of insurance reimbursement</td>
<td>0.1</td>
</tr>
<tr>
<td>Other adjustments</td>
<td>1.4</td>
</tr>
<tr>
<td>Adjusted Operating Expenses</td>
<td>$139.1</td>
</tr>
</tbody>
</table>

(1) Consists of research and development expense and selling, general and administrative expense from the Condensed Consolidated Statements of Operations.
Reconciliation of GAAP to Non-GAAP Financial Measures for the Three Months ended March 31, 2024 and 2023

(unaudited data in millions, except per share amounts)

<table>
<thead>
<tr>
<th>Adjusted Operating Income (Loss)</th>
<th>2024</th>
<th>2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>GAAP Operating Loss</td>
<td>(27.9)</td>
<td>(52.2)</td>
</tr>
<tr>
<td>Acquisition - amortization of intangible assets</td>
<td>10.7</td>
<td>10.6</td>
</tr>
<tr>
<td>Equity compensation</td>
<td>11.9</td>
<td>7.4</td>
</tr>
<tr>
<td>Real estate optimization</td>
<td>1.2</td>
<td>7.5</td>
</tr>
<tr>
<td>Transformation initiatives</td>
<td>1.9</td>
<td>4.1</td>
</tr>
<tr>
<td>Legal charges, net of insurance reimbursement</td>
<td>(0.1)</td>
<td>0.3</td>
</tr>
<tr>
<td>Other adjustments</td>
<td>1.7</td>
<td>0.4</td>
</tr>
<tr>
<td>Adjusted Operating Loss</td>
<td>(0.6)</td>
<td>(21.9)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Adjusted Net Income (Loss) (1)</th>
<th>2024</th>
<th>2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>GAAP Net Loss</td>
<td>(26.0)</td>
<td>(54.7)</td>
</tr>
<tr>
<td>Acquisition - amortization of intangible assets</td>
<td>10.7</td>
<td>10.6</td>
</tr>
<tr>
<td>Equity compensation</td>
<td>11.9</td>
<td>7.4</td>
</tr>
<tr>
<td>Real estate optimization</td>
<td>1.2</td>
<td>7.5</td>
</tr>
<tr>
<td>Transformation initiatives</td>
<td>1.9</td>
<td>4.1</td>
</tr>
<tr>
<td>Legal charges, net of insurance reimbursement</td>
<td>(0.1)</td>
<td>0.3</td>
</tr>
<tr>
<td>Other adjustments</td>
<td>0.2</td>
<td>0.4</td>
</tr>
<tr>
<td>Tax adjustments</td>
<td>(0.3)</td>
<td>7.0</td>
</tr>
<tr>
<td>Adjusted Net Loss</td>
<td>(0.5)</td>
<td>(17.4)</td>
</tr>
</tbody>
</table>

Weighted average shares outstanding:

<table>
<thead>
<tr>
<th></th>
<th>Basic</th>
<th>Diluted</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adjusted Earnings Per Share</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Basic</td>
<td>$(0.01)</td>
<td>$ (0.21)</td>
</tr>
<tr>
<td>Diluted</td>
<td>$(0.01)</td>
<td>$(0.21)</td>
</tr>
</tbody>
</table>

(1) To determine Adjusted Earnings (Loss) Per Share, or adjusted EPS.
Reconciliation of GAAP to Non-GAAP Financial Measures for the Three Months ended March 31, 2024 and 2023

(unaudited data in millions, except per share amounts)

<table>
<thead>
<tr>
<th></th>
<th>Three months ended March 31,</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>2024</td>
<td>2023</td>
<td></td>
</tr>
<tr>
<td>Adjusted EBITDA</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>GAAP Net Loss</td>
<td>(26.0)</td>
<td>(54.7)</td>
<td></td>
</tr>
<tr>
<td>Acquisition - amortization of intangible assets</td>
<td>10.7</td>
<td>10.6</td>
<td></td>
</tr>
<tr>
<td>Depreciation expense</td>
<td>4.5</td>
<td>3.0</td>
<td></td>
</tr>
<tr>
<td>Equity compensation</td>
<td>11.9</td>
<td>7.4</td>
<td></td>
</tr>
<tr>
<td>Real estate optimization(1)</td>
<td>1.2</td>
<td>7.5</td>
<td></td>
</tr>
<tr>
<td>Transformation initiatives</td>
<td>1.9</td>
<td>4.1</td>
<td></td>
</tr>
<tr>
<td>Legal charges, net of insurance reimbursement</td>
<td>0.1</td>
<td>0.3</td>
<td></td>
</tr>
<tr>
<td>Interest expense, net of interest income(2)</td>
<td>0.1</td>
<td>(0.2)</td>
<td></td>
</tr>
<tr>
<td>Other adjustments</td>
<td>0.1</td>
<td>1.2</td>
<td></td>
</tr>
<tr>
<td>Income tax expense</td>
<td>0.1</td>
<td>2.0</td>
<td></td>
</tr>
<tr>
<td>Adjusted EBITDA</td>
<td>4.0</td>
<td>(18.8)</td>
<td></td>
</tr>
</tbody>
</table>

(1) Real estate optimization includes $0.5 million and $5.8 million of depreciation expense for the three months ended March 31, 2024 and 2023, respectively.

(2) Derived from interest expense and interest income from the Condensed Consolidated Statements of Operations.

Adjusted Free Cash Flow Reconciliation for the Three Months Ended March 31, 2024 and 2023
(unaudited data in millions)

<table>
<thead>
<tr>
<th></th>
<th>Three months ended March 31,</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>2024</td>
<td>2023</td>
<td></td>
</tr>
<tr>
<td>Cash flow from operations</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Real estate optimization</td>
<td>(18.6)</td>
<td>(33.2)</td>
<td></td>
</tr>
<tr>
<td>Transformation initiatives</td>
<td>6.2</td>
<td>1.8</td>
<td></td>
</tr>
<tr>
<td>Legal charges, net of insurance reimbursement</td>
<td>1.9</td>
<td>4.1</td>
<td></td>
</tr>
<tr>
<td>Other adjustments</td>
<td>1.2</td>
<td>0.4</td>
<td></td>
</tr>
<tr>
<td>Adjusted operating cash flow</td>
<td>(9.3)</td>
<td>(25.1)</td>
<td></td>
</tr>
<tr>
<td>Capital expenditures</td>
<td>(6.7)</td>
<td>(23.5)</td>
<td></td>
</tr>
<tr>
<td>Capitalization of internal-use software costs</td>
<td>(1.9)</td>
<td>—</td>
<td></td>
</tr>
<tr>
<td>Adjusted free cash flow</td>
<td>(17.9)</td>
<td>(48.6)</td>
<td></td>
</tr>
</tbody>
</table>
Reconciliation of GAAP to Non-GAAP Financial Measures for the Three Months ended March 31, 2024 and 2023

Following is a description of the adjustments made to GAAP financial measures:

- **Acquisition** – amortization of intangible assets – represents recurring amortization charges resulting from the acquisition of intangible assets.
- **Equity compensation** – non-cash equity-based compensation provided to Myriad Genetics employees and directors.
- **Real estate optimization** – costs related to real estate initiatives. Prior to the fourth quarter 2023 reporting period, these costs were included in the transformation initiatives category in prior period reporting. With respect to the adjusted free cash flow reconciliation, the cash flow effect of real estate optimizations excludes non-cash items such as accelerated depreciation. These costs include the following:
  - For the three months ended March 31, 2024, additional rent as a result of the build-out of our new laboratories in Salt Lake City, Utah and South Francisco, California, while maintaining our current laboratories in those locations, costs associated with the voluntary termination of a lease, testing and set-up costs for equipment in our new facilities, and impairment in connection with the ceased use of one of our facilities.
  - For the three months ended March 31, 2023, additional rent as a result of the build-out of our new laboratories in Salt Lake City, Utah and South San Francisco, California, while maintaining our current laboratories in those locations, and accelerated depreciation in connection with our decision to cease the use of our former corporate headquarters in Salt Lake City, Utah.
- **Transformation initiatives** – costs related to transformation initiatives including:
  - For the three months ended March 31, 2024, consulting and professional fees.
  - For the three months ended March 31, 2023, consulting and professional fees and severance costs related to restructuring.
- **Legal charges, net of insurance reimbursement** – one-time legal expenses, net of insurance reimbursement. With respect to the adjusted free cash flow reconciliation, the cash flow effect includes cash paid for settlements in the related period.
- **Other adjustments** – other one-time non-recurring expenses including:
  - For the three months ended March 31, 2024, primarily includes a gain recognized on acquisition, changes in the fair value of contingent consideration related to acquisitions from prior years, the reclassifications of cumulative translation adjustments to income upon liquidation of an investment in a foreign entity, and costs incurred in connection with executive personnel changes.
  - For the three months ended March 31, 2023, primarily includes consulting and professional fees and changes in the fair value of contingent consideration related to acquisitions from prior years.
  - For purposes of adjusted EBITDA, other adjustments include the items listed above as well as amounts included in Other income/expense in the financial statements.
- **Depreciation expense** – depreciation expense recognized on our fixed assets.
- **Tax adjustments** – tax expense/(benefit) due to non-GAAP adjustments, differences between stock compensation recorded for book purposes as compared to the allowable tax deductions, and valuation allowance recognized against federal and state deferred tax assets in the United States.
  - As of March 31, 2024, a valuation allowance of $57.0 million was not recognized for non-GAAP purposes given our historical and forecasted positive earnings performance.
  - As of March 31, 2023, a valuation allowance of $11.6 million was not recognized for non-GAAP purposes given our historical and forecasted positive earnings performance.
  - For purposes of adjusted EBITDA, the income tax expense adjustment includes the income tax expense (benefit) recognized in the financial statements.